Prostate Imaging Using MRI +/- Contrast Enhancement

ID#: NCT04571840

Age: 18 years - 66+

Gender: Male

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: April 05, 2022

End Date: March 01, 2024

Contact Information:
Veeru Kasivisvanathan, MBBS PhD
0207 679 5057
Pramit Khetrapal, MBBS PhD
0207 679 5057
Summary: This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.

Inclusion Criteria:

1. Men at least 18 years of age referred with clinical suspicion of prostate cancer

2. Serum PSA ≤ 20ng/ml

3. Fit to undergo all procedures listed in protocol

4. Able to provide written informed consent

Exclusion Criteria:

1. Prior prostate biopsy

2. Prior treatment for prostate cancer

3. Prior prostate MRI on a previous encounter

4. Contraindication to MRI

5. Contraindication to prostate biopsy

6. Unfit to undergo any procedures listed in protocol